Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07612787 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma

Study acronym: BELAMI
StatusNot Yet Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Start date: Jun 1, 2026 to Dec 1, 2026 Eligibility criteria expanded, about 40 words · Secondary endpoints: details revised at 3 of 10 entries · Site details revised at 1 of 30 sites Show 3 more changesShow less
    • Eligibility criteria expanded, about 40 words
    • Secondary endpoints: details revised at 3 of 10 entries
    • Site details revised at 1 of 30 sites
  2. Phase changed: Phase 2 → Phase 1/2v3
  3. Eligibility criteria shortened, about 22 words Secondary endpoints: details revised at 1 of 10 entriesv2 Show 1 more changeShow less
    • Secondary endpoints: details revised at 1 of 10 entries

    See this version in full on ClinicalTrials.gov ↗

  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The BELAMI trial is an open label, multicenter, phase 2 study for patients with MM who relapsed following BCMA-directed CAR-T cells or bispecific antibodies with a Phase Ib Safety run-in. The primary hypothesis of this study is that a combination of ADC targeting BCMA and CELMoD will be efficient for these patients.
Trial Details
NCT Number NCT07612787
Lead Sponsor Centre Hospitalier Universitaire de Saint Etienne
Conditions Myeloma Multiple
Enrollment 44 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov